The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)
NCT04917796
Recruiting
This study is a randomized controlled trial of electroacupuncture (referred to as EA) versus sham acupuncture (referred to as EA) as effective treatments for Chemotherapy-Induced Peripheral Neuropathy/CIPN pain in cancer survivors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +5 locations
Conditions: Chemotherapy-induced Peripheral Neuropathy, Nerve Pain, Neuropathy, Neuropathy, Painful, Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Register for Updates
PMEG for Repair of Pararenal and Thoracoabdominal Aortic Aneurysm
NCT05195905
Recruiting
The primary objective is to evaluate the safety and effectiveness of surgeon modified endografts for the treatment of pararenal and thoracoabdominal aortic pathology in patients who are not candidate for traditional open repair due to comorbid issues and their anatomy is not amenable to commercially available endografts.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Tampa General Hospital, Tampa, Florida +1 locations
Conditions: Pararenal Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm
Register for Updates
A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT05355701
Recruiting
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07799933) administered as a single agent and in combination with other study medicines (called binimetinib) in people with solid tumors. This study is seeking participants who have an advanced solid tumor with a certain type of abnormal gene called "BRAF" and available treatments are no longer effective in controlling their cancer. All participants in this study will receive PF-07799933... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
04/14/2025
Locations: Highlands Oncology Group, Fayetteville, Arkansas +37 locations
Conditions: Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma
Register for Updates
Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies
NCT05453396
Recruiting
This phase II trial tests whether loncastuximab tesirine works to shrink tumors in patients with B-cell malignancies that have come back (relapsed) or does not respond to treatment (refractory). Loncastuximab tesirine is a monoclonal antibody, called loncastuximab, linked to a chemotherapy drug, called tesirine. Loncastuximab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Post-Transplant Lymphoproliferative Disorder, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Register for Updates
Virtual Reality Mindfulness Meditation After ACL Reconstruction
NCT05527171
Recruiting
To evaluate the effect of virtual reality mindfulness meditation on patients after ACLR, the investigators will determine the effect of virtual reality mindfulness meditation to 1) decrease self-reported injury-related fear, 2) improve poor jump-landing movement patterns, and 3) improve brain activity in women 1 to 5 years post-ACLR when compared to a virtual reality sham group.
Gender:
FEMALE
Ages:
Between 14 years and 25 years
Trial Updated:
04/14/2025
Locations: Fetzer Hall, 210 South Road, Chapel Hill, North Carolina
Conditions: Anterior Cruciate Ligament Injury
Register for Updates
Galleri in the Medicare Population
NCT05673018
Recruiting
This multi-center comparative prospective cohort study is designed to assess the real world clinical impact, including safety and test performance, of Galleri®, a blood-based multi-cancer early detection (MCED) test. The study will seek to enroll approximately 20% of the study participants from under-represented minority populations (e.g., racial / ethnic minority groups, socioeconomically disadvantaged populations, rural populations).
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/14/2025
Locations: Sutter Valley Hospitals Auburn, Auburn, California +31 locations
Conditions: Cancer
Register for Updates
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139
Recruiting
Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Angeles Clinic and Research Institute, Los Angeles, California +32 locations
Conditions: Breast Cancer, Gynecologic Cancer, HNSCC, Solid Tumors, Adult
Register for Updates
Low Sodium Oxybate in Patients With Idiopathic Hypersomnia
NCT05837091
Recruiting
Low sodium oxybate has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic hypersomnia. In this study, the researchers want to learn how low sodium oxybate impacts ability of people diagnosed with idiopathic hypersomnia to sleep for long periods of time. In addition, this study will use novel tools to determine when an individual is awake or asleep.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/14/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +3 locations
Conditions: Idiopathic Hypersomnia
Register for Updates
Phase 2a Study to Assess the Efficacy and Safety of AZD4604 in Adult Patients With Moderate-to-Severe Asthma Uncontrolled on Medium-High Dose ICS-LABA
NCT06020014
Recruiting
This is a Phase 2a, multicentre, randomised, placebo-controlled, double-blind, parallel-group study to evaluate the efficacy, safety and PK of AZD4604 administered BID using a dry-powder inhaler at one dose level over a 12-week Treatment period in adult participants with uncontrolled moderate-to-severe asthma.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/14/2025
Locations: Research Site, Birmingham, Alabama +162 locations
Conditions: Asthma
Register for Updates
IRI-EXPLORE: A Study to Test Whether BI 765845 Helps People Who Have Had a Heart Attack
NCT06139328
Recruiting
This study is open to adults aged 18 and over who have just had a heart attack. The purpose of this study is to find out whether a medicine called BI 765845 helps people who have had a heart attack. The investigators also want to test how well different doses of BI 765845 work and how they are tolerated by people who have had a heart attack. Participants are randomly assigned to receive either BI 765845 or placebo. Placebo treatments look like BI 765845 treatments but do not contain any medicin... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Valley Clinical Trials, Inc., Covina, California +87 locations
Conditions: Myocardial Infarction
Register for Updates
A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30)
NCT06215118
Recruiting
The main purpose of the study is to understand how safe and tolerable is elranatamab when given along with iberdomide. There are 2 parts to this study. Part 1 will look at how safe and tolerable is elranatamab when given with iberdomide. Part 2 will look at the correct amount of this combination that can be given to patients with relapsed or refractory multiple myeloma. Myeloma is a type of cancer that begins in plasma cells (white blood cells that produce antibodies). Refractory means a disea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Emory University Hospital Midtown, Atlanta, Georgia +29 locations
Conditions: Multiple Myeloma
Register for Updates
Understanding Patient Experience Among Asians at MD Anderson
NCT06259253
Recruiting
The purpose of this research study is to understand barriers to and facilitators of a positive patient experience for Asian patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Cancer
Register for Updates